Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer’s Disease Meeting Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : This is Zhong calling in for Tom. And congrats on the data and the progress you guys made so far. So I had a couple of questions regarding the AL001, like biomarker data for GFAP. So regarding the GFAP as a biomarker like does the level of GFAP correlate with the disease progression? And then are there any hints from the patient data on GENFI database? And I have a follow-up after that. Daniel Maslyar Yes, I can take that one. So I can say that we don't have GFAP data from the GENFI database. And as far as correlation between the biomarkers in our data set and the clinical outcome, we would love to be able to do those kinds of mathematical manipulations, but we are still dealing with a pretty small data set. So I would hesitate to certainly imply any kind of linear relationship with one or the other. I think, clearly, we can say that there is an association, I don't know if we can put a number on how strong that association is because in our Phase II data set, we did see a pretty impressive clinical improvement, and we saw a marked decline in GFAP. Now when you look at the magnitude of that decline in GFAP, I do think -- don't hold me to this right now because I don't have all of it in front of me, but that's a pretty big decline. So one would expect perhaps that the association might be stronger there. But we don't have a large enough data set to do any of the math that you would want to do.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : When I look at the CDR Plus NACC data that you presented today versus AAIC, say, I think there's 2 extra patients with data in there and 1 looks like they don't decline at all and the other looks like it declines, basically in line with the GENFI2 cohort. So can you tell me anything about those 2 patients that have difference, sort of GFAP rating, K sign or NfL levels and how they sort of responded to treatment over the course. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 12, 2021 / 9:00PM, ALEC.OQ - Alector Inc to Present to Discuss Data Presented at 2021 Clinical Trials on Alzheimer's Disease Meeting

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Okay . That's fine. And then maybe on 101, what was the rationale for doing the 15-minute slow injection on the subcutaneous dosage. That sounds pretty long to me, maybe that's just a function of an early-stage study, but a clarification on that would be great. And if that time is going to improve.